Clinical Trials Logo

Clinical Trial Summary

From Weill Cornell Medical College Center for Sleep Medicine, the investigators will recruit patients (N = 25) with previously documented moderate to severe OSA. They will receive an all-night in-home sleep study to document the severity of their OSA immediately before starting the training regimen. Scales and questionnaires measuring sleepiness, snoring, fatigue, and insomnia will be administered prior to starting the training and repeated after six weeks of training. Subjects may be removed from the study due to failing to adhere to the training regimen at anytime via remote data monitoring. The principal measure of the efficacy of the treatment will be the change in RDI, the number of abnormal breathing events per hour of sleep.


Clinical Trial Description

Obstructive sleep apnea (OSA) is a condition characterized by temporary diminutions or cessations of breathing caused by repetitive collapse of the upper airway (UA) during sleep (1). OSA is a common disorder associated with abnormalities in pharyngeal anatomy and physiology in which the muscles of the airway, which normally relax during sleep, fail to provide sufficient dilatory force to balance the contractive force from inspiratory activity (2). This force imbalance serves to either partially or completely collapse the UA, thereby preventing sufficient air from reaching the lungs. These pauses in breathing lead to blood oxygen desaturation and induce neurological arousal resulting in sleep disruption and fragmentation. The cycle of airway collapse and arousal can repeat hundreds of times per night (1). According to the National Sleep Foundation, OSA affects 18-22 million Americans, 80% of whom are undiagnosed. OSA is more prevalent among overweight and older individuals and those with reduced muscle tone, skeletal anomalies such as micrognathia or retrognathia, and airways crowded by redundant or enlarged soft tissue structures. OSA is associated with significant physiological and psychological problems. OSA results in excessive daytime sleepiness, fatigue, memory impairment, and reduced reaction time, increasing the risk for motor vehicle (3) and workplace (4) accidents. In addition, OSA sufferers face increased cardiovascular risk including hypertension, heart disease, and stroke (5). OSA has even recently been linked to increased cancer incidence (6) and mortality (7), presumably through hypoxia-induced angiogenesis. On the morning of December 1, 2013, a Metro-North passenger train derailed in the Bronx. The accident killed 4 passengers, injured 61, and caused $9 million worth of damage. Investigators determined human error was to blame: the train engineer admitted that before reaching the curve he had "gone into a daze," allowing the train to travel at three times the posted speed limit (8). A medical examination conducted after the accident diagnosed the train engineer with OSA, which hampered his ability to fully adjust his sleep patterns to the morning shift he had begun working just two weeks prior to the accident (9). The Harvard Medical School released a report in 2010 entitled, "The Price of Fatigue: The Surprising Economic Costs of Unmanaged Sleep Apnea," in which it estimated the annual economic cost of moderate to severe OSA in the United States to be $65-165B (compared to $60B for drunk driving and $150B for not wearing seatbelts), including $10-40B in OSA-related traffic accidents and $5-20B in OSA-related workplace accidents (10). Existing treatments for OSA include lifestyle modifications (11) such as weight loss, position restriction, and avoidance of muscle relaxants such as alcohol and benzodiazepine drugs. Oral appliances including mandibular advancement devices and tongue retaining devices have been increasingly employed. OSA is also treated through surgery, including tonsillectomy and uvulopalatopharyngeoplasty (UPPP) to reduce tissue crowding of the UA lumen, genioglossal advancement, and maxillomandibular advancement. The most widespread and generally effective treatment for OSA, however, remains the use of various devices for maintaining positive airway pressure (PAP) such as Continuous Positive Airway Pressure (CPAP), BiLevel Positive Airway Pressure (BiPAP), and Autotitrating (AutoPAP) devices. CPAP and related treatments are both costly and cumbersome. 40-60% of patients prescribed CPAP fail to adhere to the treatment (12; 13; 14). Patients cite comfort and lifestyle factors (sensation of claustrophobia, dry mouth, ill-fitting mask, and lack of portability of the system precluding use during travel) as reasons for abandoning treatment (15; 16). Benign Prostatic Hypertrophy (BPH), with accompanying nocturia, has also been associated with noncompliance with CPAP among older men (17). Poor compliance with CPAP is prompting the search for alternative forms of treatment for OSA. The Genioglossus (GG), which makes up most of the body of the tongue, is the major muscle responsible for protruding the tongue and is the major UA dilator that opposes collapsing force in the pharynx upon inspiration. Reduced UA dilator force in sleep is posited to contribute to the collapse of the pharynx in OSA (Schwartz 2001). A number of controlled studies have demonstrated that strengthening the GG can result in clinically significant reductions of OSA severity. In a randomized controlled trial (RCT) of OSA patients (18), a group that performed oropharyngeal exercises for 30 minutes a day for three months reduced the average apnea hypopnea index (AHI, the number of apnea and hypopnea events per hour of sleep) by almost 35% (22.4 to 14.7, P < 0.05). The exercises consisted of isometric and isotonic exercises involving the tongue. Another RCT (19) designed to increase UA dilator muscle strength demonstrated that playing the didgeridoo (an aboriginal wind instrument) six times per week for an average of 25 minutes per day over four months decreased average AHI by almost 50% (22.3 to 11.6, P < 0.01). Electrical stimulation of the hypoglossal nerve (which innervates the GG) also promotes UA patency during sleep. Hypoglossal stimulation reduced UA resistance in both healthy persons and subjects with OSA and reduced AHI in OSA subjects by over 50% (20). II. Aims The investigators assert that training the GG muscle while awake will serve to dilate the pharyngeal pathway - restriction of which results in obstructive apnea - during sleep. If confirmed, the investigators will have developed an effective behavioral treatment for OSA. The investigators anticipate it being an attractive alternative for OSA patients who are unable to acclimate to CPAP or adhere to its use for comfort or lifestyle reasons. This IRB approved clinical study is designed to determine both an effective training regimen to increase GG muscle strength as well as obtain preliminary data on the effect of tongue protrusive force training (TPFT) on OSA. In this study, the investigators will use subjects with moderate to severe OSA. OSA severity will be assessed with a sleep study conducted prior to beginning the training regimen. After six weeks of daily training, OSA severity will be measured again with a follow-up sleep study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02781701
Study type Interventional
Source Weill Medical College of Cornell University
Contact
Status Withdrawn
Phase N/A
Start date January 2017
Completion date December 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04939168 - Measuring Atomoxetine and Aroxybutynin In Patients With OSA Phase 2
Completed NCT02908529 - Atomoxetine and Oxybutynin in Obstructive Sleep Apnea Phase 1/Phase 2
Completed NCT03415633 - Validity of a Home Respiratory Polygraphy for the Diagnosis of Obstructive Sleep Apnea N/A
Completed NCT03426631 - DAW1033B2 in Obstructive Sleep Apnea Phase 1/Phase 2
Completed NCT04206449 - Sleep Thermography for Diagnosis of Obstructive Sleep Apnea (TERMOAPNEA) N/A
Active, not recruiting NCT03018912 - Validating the Use of a Subjectively Reported Sleep Vital Sign N/A
Completed NCT02549508 - Comparison Study Using APAP With and Without SensAwake in Patients With OSA and PTSD N/A
Completed NCT01249924 - The Effectiveness of Perioperative CPAP to Reduce Obstructive Sleep Apnea Related Adverse Events N/A
Completed NCT00773721 - Foam Mask - Assessment of Bioburden in a New Mask Seal Material N/A
Completed NCT02314858 - Tailored Treatment to Enhance Risk Perception in Sleep Apnea N/A
Completed NCT01476917 - The ATLAST Long-Term Study Phase 2/Phase 3
Terminated NCT00730041 - Palatal Implants in Combination With Continuous Positive Airway Pressure to Treat Obstructive Sleep Apnea Phase 4
Completed NCT00850434 - Improved Automatic CPAP Algorithm to Treat Obstructive Sleep Apnea (OSA) N/A
Enrolling by invitation NCT04538755 - DAW2020 on OSA Endotypic Traits Phase 1/Phase 2
Completed NCT02501304 - Feasibility Study of the ReVENT Sleep Apnea System N/A
Withdrawn NCT02805777 - Vent Flow Study of Prototype Nasal CPAP Mask N/A
Completed NCT02097212 - Correlation Between Trachebroncho Malacia/Hyperdynamic Airway Collapse And Obstructive Sleep Apnea N/A
Active, not recruiting NCT02295306 - Overnight Polysomnography and Respiratory Volume Monitor
Completed NCT01939938 - Pilot Study of the Comparison of the Upper Airway Dynamics of Oronasal vs Nasal Masks With PAP Treatment N/A
Terminated NCT01877928 - Post-extubation Boussignac CPAP System in Adults With Moderate to Severe Obstructive Sleep Apnea N/A